---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-23-000054"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2023-09-27T23:59:59+00:00"
generated_at: "2026-06-10T08:23:22.875384+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biohaven reports >90% IgG reduction with BHV-1300 bispecific degrader after repeat dosing

## Summary
- BHV-1300 bispecific IgG degrader achieved >90% reduction in IgG after repeat dosing in pharmacodynamic study.
- The data was disclosed in a new corporate presentation dated September 27, 2023.
- BHV-1300 targets elimination of pathogenic IgG for autoimmune disease therapy.

## SEC filing metadata
- accession: 0001935979-23-000054
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2023-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000054/0001935979-23-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000054/bhvn-20230927.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-23-000054
- JSON: https://secwatch.observer/filing/0001935979-23-000054.json
- Plain text: https://secwatch.observer/filing/0001935979-23-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.